Advair®
Fluticasone/Salmeterol is a combination ICS/LABA inhaler for maintenance treatment of asthma and COPD. One of the most prescribed respiratory medications globally.
| Dosage Form | Inhaler (DPI / MDI) |
| Strength | 100/50, 250/50, 500/50 mcg (DPI); 45/21, 115/21, 230/21 mcg (MDI) |
| Storage | Store at 20–25°C. Discard 1 month after removal from foil pouch (DPI). |
| Category | Respiratory |
| Availability | Available for Transfer |
Asthma (maintenance, patients ≥4 years); COPD (maintenance, to reduce exacerbations).
Fluticasone (ICS) reduces airway inflammation by activating glucocorticoid receptors. Salmeterol (LABA) relaxes bronchial smooth muscle via beta-2 adrenergic stimulation.
Each Burrard Pharmaceuticals technology transfer package for Fluticasone / Salmeterol includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.